A pharmacokinetic–pharmacodynamic model predicting tumour growth inhibition after intermittent administration with the mTOR kinase inhibitor AZD8055

BACKGROUND AND PURPOSE: AZD8055 is a potent orally available mTOR kinase inhibitor with in vitro and in vivo antitumour activity against a range of tumour types. Preclinical studies showed that AZD8055 induced a dose‐dependent pharmacodynamic effect in xenograft models in vivo, but a lack of underst...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Pharmacol
Main Authors: Yates, James W T, Holt, Sarah V, Logie, Armelle, Payne, Kirsty, Woods, Karen, Wilkinson, Robert W, Davies, Barry R, Guichard, Sylvie M
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2017
Assuntos:
Research Papers
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5522991/
https://ncbi.nlm.nih.gov/pubmed/28556895
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bph.13886
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados